4.7 Article

Rapid disease course in African Americans with multiple sclerosis

Journal

NEUROLOGY
Volume 75, Issue 3, Pages 217-223

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181e8e72a

Keywords

-

Funding

  1. EMD Serono/Pfizer Inc

Ask authors/readers for more resources

Objective: To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA) multiple sclerosis (MS) subpopulations in the New York State Multiple Sclerosis Consortium (NYSMSC) database. MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. Design/Methods: Distributions of patients in 6 MSSS-based severity grades were calculated for AA and WA registrants. Results: There were 419 AA and 5,809 WA patients in the NYSMSC, who had EDSS recorded during years 1-30 since symptom onset. Median EDSS was not different in AA and WA (3.5 vs 3.0, p = 0.60), whereas median MSSS in AA was higher than in WA (6.0 vs 4.8, p = 0.001). AA patients were overrepresented in the 2 most severe grades (41.5% vs 29.3% for WA) and under-represented in the 2 lowest grades (23.4% vs 35.4%; p < 0.001). In multivariable analysis (ordered logistic and median regression), MSSS for AA remained significantly higher than in WA after adjusting for age, gender, disease duration, disease type distribution, and treatment with disease-modifying therapies. Conclusions: The 6-tiered MSSS grading system is a powerful tool for comparing rate of disease progression in subpopulations of interest. MSSS-based analysis demonstrates that African ancestry is a risk factor for a more rapidly disabling disease course. Neurology (R) 2010;75:217-223

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls

Cristina M. Gaudioso, Soe Mar, T. Charles Casper, Rachel Codden, Adam Nguyen, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Carla Francisco, Mark P. Gorman, Manu S. Goyal, Jennifer Graves, Benjamin M. Greenberg, Janace Hart, Lauren Krupp, Timothy Lotze, Sona Narula, Sean J. Pittock, Mary Rensel, Moses Rodriguez, John Rose, Teri Schreiner, Jan-Mendelt Tillema, Amy Waldman, Bianca Weinstock-Guttman, Yolanda Wheeler, Emmanuelle Waubant, Eoin P. Flanagan

Summary: This study aims to determine the frequency of MOG-IgG and AQP4-IgG in pediatric-onset multiple sclerosis (POMS) patients and healthy controls, evaluate the fulfillment of diagnostic criteria in seropositive cases, compare characteristics and outcomes between POMS and MOGAD, and identify clinical features associated with final diagnosis.

ANNALS OF NEUROLOGY (2023)

Review Clinical Neurology

Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis

Omid Mirmosayyeb, Robert Zivadinov, Bianca Weinstock-Guttman, Ralph H. B. Benedict, Dejan Jakimovski

Summary: There is an association between retinal nerve fiber layer thickness and cognitive performance in patients with multiple sclerosis, particularly in terms of cognitive processing speed, verbal learning and memory, visual learning and memory, and verbal fluency.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives

Penny Pennington, Bianca Weinstock-Guttman, Channa Kolb, Dejan Jakimovski, Katherine Sacca, Ralph H. B. Benedict, Svetlana Eckert, Marc Stecker, Alexis Lizarraga, Michael G. Dwyer, Carol B. Schumacher, Niels Bergsland, Patricia Picco, Evanthia Bernitsas, Rana Zabad, Gabriel Pardo, Donald Negroski, Martin Belkin, David Hojnacki, Robert Zivadinov

Summary: Central nervous system (CNS) atrophy serves as an important indicator of ongoing neurodegeneration in persons with multiple sclerosis (PwMS). Discussing the topic of CNS atrophy with PwMS during office appointments is controversial, but recommendations include providing basic information, emphasizing the evolving nature of atrophy measurements, and individualizing the timing and language of conveying information.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Gene-environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures

Zahra Nasr, Vinicius Andreoli Schoeps, Amin Ziaei, Akash Virupakshaiah, Cameron Adams, T. Charles Casper, Michael Waltz, John Rose, Moses Rodriguez, Jan-Mendelt Tillema, Tanuja Chitnis, Jennifer S. Graves, Leslie Benson, Mary Rensel, Lauren Krupp, Amy T. Waldman, Bianca Weinstock-Guttman, Tim Lotze, Benjamin Greenberg, Gregory Aaen, Soe Mar, Teri Schreiner, Janace Hart, Steve Simpson-Yap, Clementina Mesaros, Lisa F. Barcellos, Emmanuelle Waubant

Summary: Using a case-control study, the researchers estimated the gene-environment interaction between exposure to household chemicals and genotypes for risk of paediatric-onset multiple sclerosis. The study found associations between exposure to insect repellents, weed control products, and plant/tree insect or disease control products and an increased risk of paediatric-onset multiple sclerosis. Additionally, significant interactions were found between weed control products and the NFKB1 SNP GG genotype, as well as between plant or disease control products and absence of the HLA-A*02 genotype.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC)

Dejan Jakimovski, Katelyn S. Kavak, Karen Zakalik, Timothy Coetzee, Malcolm Gottesman, Patricia K. Coyle, Robert Zivadinov, Bianca Weinstock-Guttman

Summary: Judicious diagnosis and early treatment of multiple sclerosis (MS) can significantly improve long-term disability outcomes. A retrospective analysis based on 25 years of data showed that changes in diagnostic criteria can shorten the time between symptom onset and MS diagnosis. Further improvements and implementation of MS diagnostic criteria may reduce the diagnosis lag.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis

Niels Bergsland, Michael G. Dwyer, Dejan Jakimovski, Eleonora Tavazzi, Ralph H. B. Benedict, Bianca Weinstock-Guttman, Robert Zivadinov

Summary: This study found a correlation between increased volume and inflammation of the choroid plexus (CP) and clinical disability progression in patients with multiple sclerosis (MS).

NEUROLOGY (2023)

Article Clinical Neurology

Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder

Raffaella Pizzolato Umeton, Michael Waltz, Gregory S. Aaen, Leslie Benson, Mark Gorman, Manu Goyal, Jennifer S. Graves, Yolanda Harris, Lauren Krupp, Timothy E. Lotze, Nikita M. Shukla, Soe Mar, Jayne Ness, Mary Rensel, Teri Schreiner, Jan-Mendelt Tillema, Shelly Roalstad, Moses Rodriguez, John Rose, Emmanuelle Waubant, Bianca Weinstock-Guttman, Charles Casper, Tanuja Chitnis

Summary: This retrospective cohort study evaluated cases of children with NMOSD and found that the use of disease-modifying treatments, particularly rituximab, is associated with a lowered annualized relapse rate in children with NMOSD AQP4+.

NEUROLOGY (2023)

Article Neurosciences

Additive interaction between dietary inflammatory index and some key risk factors of multiple sclerosis: a population-based incident case-control study

Ibrahim Abdollahpour, Yahya Salimi, Saharnaz Nedjat, Maryam Nazemipour, Mohammad Ali Mansournia, Bianca Weinstock-Guttman

Summary: The study found that there is an additive interaction between Dietary Inflammatory Index (DII) and drug abuse, gender, and history of depression in multiple sclerosis (MS). However, there is no evidence of multiplicative interaction between DII and other risk factors of MS.

NUTRITIONAL NEUROSCIENCE (2023)

Letter Clinical Neurology

It's not always an infection: Pyoderma gangrenosum of the urogenital tract in two patients with multiple sclerosis treated with rituximab

Erica Parrotta, Hannah Kopinsky, Jennifer Abate, Lana Zhovtis Ryerson, Lauren B. Krupp

Summary: B-cell depleting therapies such as rituximab and ocrelizumab, commonly used for Multiple Sclerosis treatment, have increased risks of adverse reactions, one of which is the rarely reported pyoderma gangrenosum (PG), an inflammatory, ulcerative skin disease. We describe two patients with Relapsing-Remitting Multiple Sclerosis who developed PG while on rituximab, and their diagnoses were supported by clinical symptoms, biopsy reports, and response to treatment.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Immunology

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study

Dejan Jakimovski, Svetlana P. Eckert, Omid Mirmosayyeb, Sangharsha Thapa, Penny Pennington, David Hojnacki, Bianca Weinstock-Guttman

Summary: This study aimed to determine the real-world efficacy of tixagevimab and cilgavimab (Evusheld (TM)) in preventing breakthrough COVID-19 infections in immunosuppressed persons with neuroinflammatory diseases (pwNID). The results showed that pwNID treated with tixagevimab and cilgavimab had a significantly lower rate of COVID-19 infections and milder severity compared to the control group.

VACCINES (2023)

Article Clinical Neurology

Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2

Teri Schreiner, Molly Wilson-Murphy, Jan Mendelt-Tillema, Michael Waltz, Rachel Codden, Leslie Benson, Mark Gorman, Manu Goyal, Lauren Krupp, Tim Lotze, Soe Mar, Jayne Ness, Mary Rensel, Shelly Roalstad, Moses Rodriguez, John Rose, Nikita Shukla, Emmanuelle Waubant, Yolanda Wheeler, T. Charles Casper, Tanuja Chitnis

Summary: This study found a higher prevalence of SARS-CoV-2 infection among pediatric patients with POMS and related disorders, with a higher risk of hospitalization and ICU admission for those receiving B-cell depleting therapy, suggesting a higher risk of severe infection in this population.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Clinical Neurology

Silent findings: Examination of asymptomatic demyelination in a pediatric US cohort

Vikram Bhise, Michael Waltz, T. Charles Casper, Gregory Aaen, Leslie Benson, Tanuja Chitnis, Mark Gorman, Manu S. Goyal, Yolanda Wheeler, Timothy Lotze, Soe Mar, Mary Rensel, Aaron Abrams, Moses Rodriguez, John Rose, Teri Schreiner, Nikita Shukla, Emmanuelle Waubant, Bianca Weinstock-Guttman, Jayne Ness, Lauren Krupp, Jan Mendelt-Tillema

Summary: In this study, we aimed to characterize a US cohort of children with incidental MRI findings suspect for demyelination and identify predictors of clinical and radiologic outcomes. The results showed that one-third of the patients had a clinical attack and three-quarters developed new MRI activity during a mean follow-up time of 3.7 years. Sex, presence of infratentorial lesions, T1 hypointense lesions, juxtacortical lesion count, and callosal lesions were found to be predictors of disease progression. Interestingly, T1 hypointense and infratentorial lesions, typically associated with worse outcomes, were predictive of delayed disease progression on imaging in subgroup analysis. Additionally, currently utilized diagnostic criteria did not provide statistically significant benefit in risk stratification, highlighting the need for further study.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Article Clinical Neurology

Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon beta-1a users

Caila B. Vaughn, Katelyn S. Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman

Summary: A large retrospective study found that patient-reported limitations in physical and mental symptoms can predict future disability worsening in multiple sclerosis (MS) patients treated with intramuscular interferon-beta medication. The study also identified lower extremities limitations and fatigue as the most predictive factors for disability worsening.

NEURODEGENERATIVE DISEASE MANAGEMENT (2023)

Article Clinical Neurology

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis

Dejan Jakimovski, Taylor R. Wicks, Niels Bergsland, Michael G. Dwyer, Bianca Weinstock-Guttman, Robert Zivadinov

Summary: This study found that patient-reported outcomes (PROs) are associated with concurrent and future impairments in persons with multiple sclerosis (pwMS). The structural and pathological relationships with PROs in pwMS have not been elucidated.

DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE (2023)

No Data Available